Research-led biotechnology
exRNA Therapeutics brings together RNA biology, oligonucleotide systems and microbial research to explore precise approaches for complex disease biology.
Conceptual figure: two strands entering register across an interaction region. Not a real sequence or structure.
Scientific position
RNA and oligonucleotide research is our primary focus. Two further areas of research sit alongside it.
01
Primary focus
We study how nucleic-acid sequence and higher-order organization influence molecular behaviour, and we design and evaluate oligonucleotide architectures against that understanding.
Sequence is only the first layer of information. Architecture, molecular specificity and characterization each constrain one another, so an oligonucleotide is treated as a system rather than as a single molecule.
02
Research area
We study central nervous system, neurological and genetically driven disease biology as areas of research.
These are research areas, not clinical programmes. We describe no candidate, no molecular target and no therapeutic outcome, and nothing here is a claim about treating any condition.
03
Supporting research
We investigate beneficial microbial systems and their molecular outputs as research platforms.
This is preclinical scientific research into microbial systems and the molecules they produce — characterization and biological investigation, not a consumer or wellness product.
How we work
A high-level view of how a research question progresses. It is a conceptual sequence rather than a claim that every project reaches every stage.
01
A question is written down, along with what would count as an informative answer.
02
Whether the question can be approached at the molecular level is assessed before any design work.
03
Candidate architectures are designed on paper and in silico, weighing specificity against practicality.
04
Material is characterized for identity, composition and behaviour under defined conditions.
05
Behaviour is observed in a cell-based context rather than in isolation.
06
Research-stage evaluation. Findings are treated as provisional; no clinical or human-subject work is conducted.
Research area
Neurological and genetically driven disease biology is one of the areas we study. Our interest is in the molecular organization underneath it.
Conditions with a genetic basis are, at some level, questions about sequence and about what the molecular machinery does with it. That is the level at which we work, and it is why this biology sits close to our RNA and oligonucleotide research rather than apart from it.
This is early-stage research. We are not describing a clinical programme, a candidate, a molecular target or a route into any tissue, and nothing on this page should be read as a claim about treating a neurological condition.
Abstract network figure — not an anatomical or pathway diagram.
Research area
We study beneficial microbial systems and the molecules they produce as serious preclinical research — not as a consumer or wellness product.
Microbial communities are productive molecular systems. They generate a wide range of outputs, respond to their environment, and maintain organization across scales far larger than a single cell, which makes them a useful place to ask questions about molecular organization.
Our work here is characterization and biological investigation at a research and preclinical stage. We publish no strain identity, no formulation and no product claim of any kind.
Establishing identity, composition and behaviour of microbial material under defined research conditions.
Studying molecular outputs and how they behave in a controlled biological context.
Assessing which research candidates merit further study, on written criteria set in advance.
Research-stage evaluation only. No clinical or human-subject work is conducted or described.
Capabilities
Computational, molecular, cell-based and preclinical research capabilities, supported by documented research records.
Computational analysis relating sequence information to structural possibility, used to frame research questions before laboratory work.
Read moreCharacterization of molecular material to establish identity, composition and behaviour under defined research conditions.
Read moreCell-based research used to observe molecular behaviour in a biological context rather than in isolation.
Read moreEvaluation at a research and preclinical stage. No clinical or human-subject research is conducted or described.
Read moreDocumentation and record-keeping that allow an observation to be traced back to the conditions that produced it.
Read moreThe company
Founded in 2021, exRNA Therapeutics is a research-led biotechnology company operating from Bodh Gaya, Bihar. Our work spans nucleic-acid structure, oligonucleotide systems and microbial biology, supported by computational, molecular, cell-based and preclinical research capabilities.
More about the companyFounded
2021
Operating from
Bodh Gaya, Bihar, India
Stage
Research and preclinical
Enquiries
Research principles
All work described publicly is at a research or preclinical stage. We do not describe clinical activity, approved products or regulatory outcomes.
Our public materials make no claim of therapeutic benefit, no comparison to any other approach or product, and no assertion about outcomes.
We describe our areas of research at a high level. Research-stage detail — including molecular designs, materials, methods and results — is not published.
We aim to be precise about what is established and what is not. Where a question is unresolved, we describe it as unresolved.
Read the science, talk to the company, or look at how we work.